Janssen's Darzalex (daratumumab- SC) Combination Regimen Receives Health Canada's Approval for Patients with Newly Diagnosed Light Chain Amyloidosis
Shots:
- The approval is based on results from the P-III ANDROMEDA (AMY3001) study involves assessing the safety and efficacy of Darzalex (1800mg- SC- qw) + bortezomib- cyclophosphamide- and dexamethasone (VCd) vs VCd alone in 388 patients with newly diagnosed AL amyloidosis
- The study showed higher hematologic response rate in ITT population (53% vs 18%)- patients who received VCd- 74% patients were exposed to the regimen for 6mos. or longer- while 32% were exposed for longer than 1yr.
- Darzalex SC is a CD38-directed mAb- became the first SC therapy to be approved in Canada for AL amyloidosis. Health Canada review was conducted under Project Orbis
Ref: Newswire Canada | Image: Janssen
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com